Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens

Cancer Chemotherapy and Pharmacology
N BaizeF X Caroli-Bosc

Abstract

To determine the safety and the efficacy of paclitaxel and capecitabine as second-line combination chemotherapy after failure of platinum regimens in advanced gastric cancer. Patients with histologically proven gastric cancer and measurable metastatic disease received capecitabine 825 mg/m(2) twice daily (1,650 mg/m(2) per day) on days 1-14 and paclitaxel 175 mg/m(2) by intravenous infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities. Between June 2003 and October 2005, 26 patients, of median age 59 years (range 41-84 years) were included in the study and were treated by paclitaxel/capecitabine combination. Overall response rate was 34.6% (95%CI = 17.2-55.7%) with one complete response and 42.3% (95%CI = 17.2-55.7%) of patients achieved a stable disease. Median progression-free survival was 4.5 months (95%CI = 4-4.5 months). Median overall survival was 7.5 months (95%CI = 6-10 months). Cumulated overall survival including cisplatin regimens was 15.5 months (95%CI = 11-18 months). Grade 3/4 adverse events included alopecia (30.8%), neutropenia (11.5%), hand foot skin reaction (11.5%), neuropathy (11.5%), arthralgias (7.5%), and anemia (3.8%). Paclitaxel and capecitabine combination was safe and ef...Continue Reading

References

Mar 1, 1978·Cancer·J B DupontI Cohn
Feb 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusP O Sjödén
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Jun 23, 1998·Anti-cancer Drugs·S CascinuG Catalano
Jul 4, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Villalona-CaleroE K Rowinsky
Jul 12, 2002·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kensei YamaguchiUNKNOWN Paclitaxel Gastric Cancer Study Group in Japan
Apr 17, 2003·Oncology·Wasaburo KoizumiUNKNOWN Clinical Study Group of Capecitabine
Dec 9, 2003·British Journal of Cancer·J P Guastalla, V Diéras
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y S HongJ Y Cho
Jan 24, 2006·Anti-cancer Drugs·Junichi SakamotoUNKNOWN Clinical Study Group of Capecitabine
Feb 21, 2006·World Journal of Gastroenterology : WJG·Katherine D Crew, Alfred I Neugut
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farin KamangarWilliam F Anderson
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemUNKNOWN V325 Study Group
Sep 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G RosatiL Manzione
Sep 20, 2008·Journal of Surgical Oncology·Joong-Min ParkChong-Suk Kim

❮ Previous
Next ❯

Citations

Apr 20, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Tetsuya HamaguchiUNKNOWN Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group
Jul 26, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Hiroya Takiuchi
Dec 25, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J GaoL Shen
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong
Feb 24, 2010·Cancer Treatment Reviews·Derek G PowerManish A Shah
Sep 4, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Yuksel KucukzeybekMustafa Oktay Tarhan
Nov 12, 2015·World Journal of Gastroenterology : WJG·Dheepak KanagavelSergei Tjulandin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.